Canaccord, Citigroup, and BTIG reduce price targets for Exact Sciences stock; TheStreet lowers rating.
Canaccord Genuity Group has lowered its price target for Exact Sciences (NASDAQ:EXAS) from $90 to $85, while maintaining a buy rating on the medical research company's stock. Other analysts have also issued reports on EXAS, with Citigroup reducing their price target from $100 to $80 and setting a buy rating, and BTIG Research reducing their target from $85 to $80 with a buy rating. TheStreet lowered its rating for Exact Sciences from c- to d+.
May 12, 2024
3 Articles